Pfizer Earnings Estimate

PFE -  USA Stock  

USD 50.40  0.94  1.83%

Many public companies, such as Pfizer, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Pfizer's earnings estimates, investors can diagnose different trends across Pfizer's analyst sentiment over time as well as compare current estimates against different timeframes.
Pfizer is projected to generate 4.18 in earnings per share on the 31st of December 2021. Pfizer earnings estimates module stress-tests analyst consensus about projected Pfizer Inc EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Please check Your Equity Center.
  
Refresh

Pfizer Earnings Estimation Breakdown

Calculation of earning per share of Pfizer Inc is based on official Zacks consensus of 5 analysts regarding Pfizer future annual earnings. Given the historical accuracy of 90.61%, the future earnings per share of Pfizer is estimated to be 4.18 with the lowest and highest values of 4.13 and 4.25, respectively. Please note that this consensus of annual earnings estimates for Pfizer Inc is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS 3.5
4.13
Lowest
Expected EPS 4.18
4.25
Highest

Pfizer Earnings Projection Consensus

Suppose the current estimates of Pfizer's value are higher than the current market price of the Pfizer stock. In this case, investors may conclude that Pfizer is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Pfizer's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

5

90.61%

3.5

4.18

Pfizer Earnings per Share Projection vs Actual

Actual Earning per Share of Pfizer refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Pfizer Inc predict the company's earnings will be in the future. The higher the earnings per share of Pfizer, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Pfizer Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Pfizer, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Pfizer should always be considered in relation to other companies to make a more educated investment decision.

Pfizer Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Pfizer's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-03
2022-03-311.471.670.213 
2022-02-08
2021-12-310.871.080.2124 
2021-11-02
2021-09-301.08511.340.254923 
2021-07-28
2021-06-300.97791.070.0921
2021-05-04
2021-03-310.77740.930.152619 
2021-02-02
2020-12-310.46480.42-0.0448
2020-10-27
2020-09-300.71310.720.0069
2020-07-28
2020-06-300.66030.780.119718 
2020-04-28
2020-03-310.72740.80.0726
2020-01-28
2019-12-310.57580.55-0.0258
2019-10-29
2019-09-300.61940.750.130621 
2019-07-29
2019-06-300.75490.80.0451
2019-04-30
2019-03-310.7520.850.09813 
2019-01-29
2018-12-310.63350.640.0065
2018-10-30
2018-09-300.74590.780.0341
2018-07-31
2018-06-300.74390.810.0661
2018-05-01
2018-03-310.74320.770.0268
2018-01-30
2017-12-310.56120.620.058810 
2017-10-31
2017-09-300.64620.670.0238
2017-08-01
2017-06-300.65880.670.0112
2017-05-02
2017-03-310.67140.690.0186
2017-01-31
2016-12-310.50590.47-0.0359
2016-11-01
2016-09-300.61990.61-0.0099
2016-08-02
2016-06-300.62250.640.0175
2016-05-03
2016-03-310.55280.670.117221 
2016-02-02
2015-12-310.52270.530.0073
2015-10-27
2015-09-300.510.60.0917 
2015-07-28
2015-06-300.520.560.04
2015-04-28
2015-03-310.490.510.02
2015-01-27
2014-12-310.530.540.01
2014-10-28
2014-09-300.550.570.02
2014-07-29
2014-06-300.570.580.01
2014-05-05
2014-03-310.550.570.02
2014-01-28
2013-12-310.520.560.04
2013-10-29
2013-09-300.560.580.02
2013-07-30
2013-06-300.550.560.01
2013-04-30
2013-03-310.550.54-0.01
2013-01-29
2012-12-310.440.470.03
2012-11-01
2012-09-300.530.530
2012-07-31
2012-06-300.540.620.0814 
2012-05-01
2012-03-310.560.580.02
2012-01-31
2011-12-310.470.50.03
2011-11-01
2011-09-300.560.620.0610 
2011-08-02
2011-06-300.590.60.01
2011-05-03
2011-03-310.590.60.01
2011-02-01
2010-12-310.460.470.01
2010-11-02
2010-09-300.510.540.03
2010-08-03
2010-06-300.520.620.119 
2010-05-04
2010-03-310.530.60.0713 
2010-02-03
2009-12-310.50.49-0.01
2009-10-20
2009-09-300.480.510.03
2009-07-22
2009-06-300.470.480.01
2009-04-28
2009-03-310.490.540.0510 
2009-01-26
2008-12-310.590.650.0610 
2008-10-21
2008-09-300.60.620.02
2008-07-23
2008-06-300.540.550.01
2008-04-17
2008-03-310.660.61-0.05
2008-01-23
2007-12-310.470.520.0510 
2007-10-18
2007-09-300.530.580.05
2007-07-18
2007-06-300.50.42-0.0816 
2007-04-20
2007-03-310.570.680.1119 
2007-01-22
2006-12-310.420.430.01
2006-10-19
2006-09-300.450.540.0920 
2006-07-20
2006-06-300.480.50.02
2006-04-19
2006-03-310.530.610.0815 
2006-01-19
2005-12-310.420.510.0921 
2005-10-20
2005-09-300.480.510.03
2005-07-20
2005-06-300.440.460.02
2005-04-19
2005-03-310.530.540.01
2005-01-19
2004-12-310.590.58-0.01
2004-10-20
2004-09-300.540.550.01
2004-07-21
2004-06-300.470.470
2004-04-20
2004-03-310.510.520.01
2004-01-22
2003-12-310.510.530.02
2003-10-22
2003-09-300.440.470.03
2003-07-25
2003-06-300.290.30.01
2003-04-22
2003-03-310.440.450.01
2003-01-22
2002-12-310.470.480.01
2002-10-16
2002-09-300.390.390
2002-07-15
2002-06-300.320.330.01
2002-04-17
2002-03-310.390.390
2002-01-23
2001-12-310.340.340
2001-10-17
2001-09-300.330.340.01
2001-07-17
2001-06-300.290.30.01
2001-04-18
2001-03-310.310.330.02
2001-01-24
2000-12-310.270.270
2000-10-24
2000-09-300.260.270.01
2000-07-24
2000-06-300.220.230.01
2000-04-18
2000-03-310.250.280.0312 
2000-01-18
1999-12-310.230.250.02
1999-10-19
1999-09-300.210.230.02
1999-07-19
1999-06-300.170.190.0211 
1999-04-15
1999-03-310.210.210
1999-01-19
1998-12-310.170.180.01
1998-10-13
1998-09-300.190.17-0.0210 
1998-07-09
1998-06-300.150.170.0213 
1998-04-14
1998-03-310.180.180
1998-01-20
1997-12-310.140.140
1997-10-14
1997-09-300.150.150
1997-07-15
1997-06-300.120.120
1997-04-15
1997-03-310.160.160
1997-01-16
1996-12-310.130.130
1996-10-14
1996-09-300.130.130
1996-07-17
1996-06-300.10.10
1996-04-16
1996-03-310.130.140.01

About Pfizer Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Pfizer earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Pfizer estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Pfizer fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 78500 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pair Correlation Now

   

Pair Correlation

Compare performance and examine fundamental relationship between any two equity instruments
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.